-
Piper Jaffray Maintains Overweight on Medtronic
Wednesday, May 25, 2011 - 8:33am | 142Piper Jaffray is out with its report today on Medtronic (NYSE: MDT), maintaining Overweight. In a note to clients, Piper Jaffray writes, "Growth continued to elude MDT; we see the value thesis of strong global brands, consistent cash flow, and a low multiple, remaining intact. In our view, if the...
-
Deutsche Bank Maintains Hold on Boston Scientific
Wednesday, May 25, 2011 - 8:25am | 102Deutsche Bank is out with its report today on Boston Scientific (NYSE: BSX), maintaining Hold. In a note to clients, Deutsche Bank writes, "Medtronic's results did not change our view on BSX shares. MDT's results underscore the ICD market is challenged (more than expected) and when combined with...
-
UPDATE: Piper Jaffray Raises PT on Hill-Rom Holdings to $52
Wednesday, May 25, 2011 - 8:20am | 142Piper Jaffray is out with its report today on Hill-Rom Holdings (NYSE: HRC), raising its PT from $51 to $52. In a note to clients, Piper Jaffray writes, "Hill-Rom's LRP lays out a 5-year flight path for top-line growth and margin expansion right in line with our expectations, while also leaving...
-
J.P. Morgan Comments On St Jude Market Forecast
Wednesday, May 25, 2011 - 8:11am | 87According to J.P. Morgan, St Jude Medical (NYSE: STJ) has updated several MedTech market models on the back of Medtronic's results on Tuesday, and along with them its company specific model for STJ, BSX, JNJ, and ABT. J.P. Morgan said that, “As it pertains to St. Jude, we've trimmed our 2011-12...
-
Benzinga's Top Upgrades
Wednesday, May 25, 2011 - 8:08am | 137JP Morgan upgraded NTELOS Holdings Corp (NASDAQ: NTLS) from “neutral” to “overweight.” NTLS's shares closed at $19.05 yesterday. NTLS's PEG ratio is 0.45. Analysts at Bank of America upgraded Con-way Inc (NYSE: CNW) from “neutral” to “buy.” CNW's shares closed at $37.41 yesterday. Con-way's...
-
J.P. Morgan Comments On Medtronic F4Q11 Results
Wednesday, May 25, 2011 - 8:08am | 102According to J.P. Morgan, Medtronic (NYSE: MDT) reported mixed F4Q11 results Tuesday morning, as adjusted EPS of $0.90 (+1.2%) fell $0.02 short of consensus. J.P. Morgan said that on the top line, revenues of $4.295B (+2.4%) came in $10M better than the Street, but organic growth was just 0.2% in...
-
Angeion Announces CEO Departure and Names Interim CEO, Gregg O. Lehman Interim CEO Effective Immediately
Wednesday, May 25, 2011 - 8:05am | 151Angeion Corporation (NASDAQ: ANGN) today announced that Philip I. Smith has resigned as the Chief Executive Officer of Angeion Corporation following the mutual decision of Mr. Smith and the Company's board of directors. Mr. Smith became President and CEO of the Company effective January 1, 2011...
-
Bank of America Merrill Lynch Reiterates Buy on Nuvasive
Wednesday, May 25, 2011 - 8:00am | 150Bank of America Merrill Lynch is out with its report today on Nuvasive (NASDAQ: NUVA), reiterating Buy. In a note to clients, Bank of America Merrill Lynch writes, "At just 2.4x 2011E EV/sales NUVA trades well below peer valuations primarily because investors are worried about the spine mkt....
-
Jefferies & Company Reports on Medtronic
Wednesday, May 25, 2011 - 7:53am | 123Jefferies & Company commented on Medtronic (NYSE: MDT) in a report released yesterday. In the report, Jefferies was mixed in its assessment of the company. Jefferies writes, "Fiscal 4Q11 results repeated the now rote script at Medtronic: weak CRM and Spine results not fully offset by growth in...
-
Jefferies Comments on Stryker 1Q Knee Results
Wednesday, May 25, 2011 - 7:53am | 153Stryker's (NYSE: SYK) 1Q knee results across the board were down from 4Q, Jefferies reports. “The worldwide market was flat and U.S. was down 4%; sequentially, U.S. was 500bp slower,” Jefferies writes. “It is a bit confounding that knees decelerated so precipitously in 1Q given that several...
-
Jefferies Comments on Integra Life-Sciences Acquisition
Wednesday, May 25, 2011 - 7:49am | 88Integra Life-Sciences (NASDAQ: IART) announced its acquisition of privately-held SeaSpine for $89M cash, “which effectively doubles the company's distribution capacity and revenue base in the U.S. spinal hardware market,” Jefferies reports. “SeaSpine generated ~$50M in 2010 revenues and at 1.8x...
-
Deutsche Bank Maintains Hold on Stryker
Wednesday, May 25, 2011 - 7:48am | 140Deutsche Bank is out with its report today on Stryker (NYSE: SYK), maintaining Hold. In a note to clients, Deutsche Bank writes, "Hill-Rom (NYSE: HRC) hosted an investor day on Tuesday providing its long-range plan and views on the market HRC competes with Stryker's Medical franchise (8% of total...
-
Piper Jaffray Raises PT on Hill-Rom To $52
Wednesday, May 25, 2011 - 7:31am | 27Piper Jaffray has raised the price target on Hill-Rom Holdings (NYSE: HRC) from $51 to $52 and maintains its Overweight rating.
-
Boston Scientific Announces FDA Approval and U.S. Launch of PROMUS® 2.25 mm Everolimus-Eluting Coronary Stent System
Wednesday, May 25, 2011 - 7:01am | 228Boston Scientific Corporation (NYSE: BSX) today announced it has received approval from the U.S. Food and Drug Administration (FDA) to market its 2.25 mm PROMUS ^® Everolimus-Eluting Coronary Stent System for use in vessels as small as 2.25 mm in diameter. The Company plans to immediately launch...
-
Morgan Stanley Provides Color on Medtronic, Equal-Weight
Wednesday, May 25, 2011 - 6:49am | 184Morgan Stanley provided color on Medtronic (NYSE: MDT) after the company announced its quarterly report. In a research report published today, Morgan Stanley expressed its belief that the earnings per share guidance of $3.43 - $3.50 might be conservative. In the report, Morgan Stanley states, "...